オハイオにおける胃癌の臨床試験
オハイオ内の拠点で、胃癌に関する24件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- 他1件
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/02更新 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- 他44件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Local Institution - 0443, Cleveland
- Local Institution - 0222, Cleveland
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07221149A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07392892Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
被験者募集中第2相
18歳〜130歳 · 全性別 · 2026/09/23更新 · NCT05489211Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
- Cleveland Clinic, Cleveland
- Kettering, Kettering
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07217704EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
被験者募集中
18歳以上 · 全性別 · 2026/09/15更新 · NCT06263088A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University Hospital Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07070232A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT03526835A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Ohio State University, Columbus
被験者募集中第1/2相
18歳〜90歳 · 全性別 · 2026/07/06更新 · NCT06710756Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Stefanie Spielman Comprehensive Breast Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/27更新 · NCT06395519A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Cleveland Clinic, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/02/27更新 · NCT06532006cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/12/11更新 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT0345277464Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1/2相
15歳以上 · 全性別 · 2025/08/12更新 · NCT06298916ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。